Ontogenetic changes in serum S100B in Down syndrome patients.
BACKGROUND
It has been shown that Down syndrome (DS) patients have elevated S100B levels in brain tissue.


METHODS
Measurements of S100B were performed in serum samples from 48 DS patients and 42 ostensibly healthy age-matched controls.


RESULTS
We observed higher levels of S100B in the DS group than in the control group. Moreover, serum S100B in DS patients was not age-dependent as it is in normal individuals.


CONCLUSIONS
The higher levels of S100B in DS patients may reflect a general and persistent increase in the extracellular space and may be associated with neurodegenerative lesions observed in DS patients.
Netto
Cristina B O
CB
Dept. Bioquimica, ICBS, UFRGS, Rua Euripedes Monteiro Duarte 10/305, Porto Alegre, RS, 90830-250, Brazil. cristina.netto@ufrgs.br
Portela
Luis V
LV
Ferreira
Cristina T
CT
Kieling
Carlos
C
Matte
Ursula
U
Felix
Têmis
T
da Silveira
Themis Reverbel
TR
Souza
Diogo O
DO
Gonçalves
Carlos-Alberto
CA
Giugliani
Roberto
R
D000375:Aging; D002648:Child; D002675:Child, Preschool; D004314:Down Syndrome / Q000097:blood*; D006801:Humans; D007223:Infant; D009414:Nerve Growth Factors / Q000097:blood*; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood*
D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human